Table 2.
Laboratory data according to anakinra and placebo.
| Anakinra (n = 64) | Placebo (n = 35) | P-value | |
|---|---|---|---|
| CKMB-AUC, ng/mL*d | 2219 [1130–3821] | 2351 [765–4668] | 0.859 |
| At admission | |||
| Hemoglobin, g/dL | 14.5 [13.4–15.3] | 14.4 [13.6–15.6] | 0.692 |
| Hematocrit, % | 43 [40–47] | 42 [41–44] | 0.558 |
| White blood cell, 109/L | 10.85 [8.52–13.90] | 11.40 [9.20–15.07] | 0.692 |
| Absolute neutrophil count, 109/L | 7.45 [4.72–11.05] | 7.30 [5.20–12.50] | 0.622 |
| Absolute lymphocyte count, 109/L | 2.05 [1.3–3.02] | 1.8 [1.30–2.55] | 0.699 |
| Absolute monocyte count, 109/L | 0.60 [0.40–0.80] | 0.70 [.50–0.80] | 0.185 |
| Absolute eosinophil count, 109/L | 0.10 [0.00–0.125] | 0.10 [0.00–0.20] | 0.279 |
| Neutrophil to lymphocyte ratio | 4.29 [1.99–7.51] | 3.71 [2.08–8.37] | 0.719 |
| Creatinine, mg/dL | 0.94 [0.78–1.10] | 1.00 [0.89–1.34] | 0.063 |
| NTproBNP, pg/mL | 52.50 [22.00–217.59] | 95.5 [23.75–244.00] | 0.614 |
| At 72 h | |||
| White blood cell, 109/L | 7.50 [6.20–8.35] | 8.30 [7.20–9.80] | |
| % Change from baseline | − 35% [− 48 to − 24] | − 21% [− 34 to − 10] | 0.008 |
| Absolute neutrophil count, 109/L | 4.15 [3.22–5.07] | 5.40 [4.65–5.40] | |
| % Change from baseline | − 48% [− 60 to − 22] | − 27% [− 46 to − 5] | 0.004 |
| Absolute lymphocyte count, 109/L | 2.15 [1.50–2.60] | 1.80 [1.40–2.20] | |
| % Change from baseline | − 7% [− 4% to + 32] | − 6% [− 38 to + 22] | 0.657 |
| Absolute monocyte count, 109/L | 0.60 [0.50–0.80] | 0.80 [0.60–0.95] | |
| % Change from baseline | + 11% [− 29 to + 51] | + 14% [− 13 to + 47] | 0.604 |
| Absolute eosinophil count, 109/L | 0.20 [0.10–0.30] | 0.10 [0.10–0.30] | |
| % Change from baseline | + 50% [0 to + 100] | 0% [− 50 to + 62] | 0.022 |
| Neutrophil to lymphocyte ratio | 1.90 [1.37–3.22] | 3.35 [2.6 | |
| % Change from baseline | − 54% [− 13 to + 70] | − 13% [− 58 to + 70] | 0.047 |
| At 14 days | |||
| White blood cell, 109/L | 7.10 [5.70–9.40] | 8.60 [6.92–10.5] | |
| % Change from baseline | − 33% [− 45 to − 22] | − 20% [− 41 to − 9] | 0.044 |
| Absolute neutrophil count, 109/L | 4.60 [3.30–5.50] | 5.50 [4.00–7.15] | |
| % Change from baseline | − 42% [− 61 to − 25] | − 32% [− 51% to − 1] | 0.067 |
| Absolute lymphocyte count, 109/L | 2.10 [1.50–2.60] | 2.00 [1.70–2.27] | |
| % Change from baseline | 0% [− 32 to + 32] | + 10% [− 22 to 40] | 0.313 |
| Absolute monocyte count, 109/L | 0.60 [0.50–0.80] | 0.65 [0.50–0.70] | |
| % Change from baseline | − 5% [− 30 to + 26] | 0% [− 20 to + 3] | 0.989 |
| Absolute eosinophil count, 109/L | 0.20 [0.10–0.30] | 0.20 [0.20–0.30] | |
| % Change from baseline | + 100% [0 to + 200] | 0% [− 30 to + 100] | 0.043 |
| Neutrophil to lymphocyte ratio | 2.26 [1.34–3.25] | 2.89 [1.93–3.68] | |
| % Change from baseline | − 50% [− 67 to 10] | − 36% [− 65 to + 3] | 0.500 |
| At 3 months | |||
| White blood cell, 109/L | 6.90 [5.90–8.60] | 7.55 [6.05–9.47] | |
| % Change from baseline | − 41% [− 49 to − 16] | − 30% [− 44 to − 19] | 0.301 |
| Absolute neutrophil count, 109/L | 4.20 [3.30–5.20] | 4.35 [3.50–5.70] | |
| % Change from baseline | − 53% [− 61 to − 25] | − 43% [− 54 to − 33] | 0.298 |
| Absolute lymphocyte count, 109/L | 2.10 [1.50–2.60] | 2.00 [1.57–2.30] | |
| % Change from baseline | − 3% [− 29 to + 35] | + 8% [− 28 to + 59] | 0.584 |
| Absolute monocyte count, 109/L | 0.60 [0.50–0.70] | 0.65 [0.50–0.70] | |
| % Change from baseline | − 10% [− 28 to + 24] | 7% [− 30 to + 25] | 0.748 |
| Absolute eosinophil count, 109/L | 0.20 [0.10–0.20] | 0.20 [0.10–0.32] | |
| % Change from baseline | 0% [0 to 100] | + 33% [0–100%] | 0.764 |
| Neutrophil to lymphocyte ratio | 2.09 [1.35–2.85] | 2.61 [1.73–3.24] | |
| % Change from baseline | − 51% [− 70 to 17] | − 42% [− 75 to − 9] | 0.964 |
Data are expressed as median [interquartile range]. P-values in bold character indicate significant values (< 0.05) for difference between groups.
CKMB-AUC Creatine kinase-MB area under the curve, CRP-AUC C-reactive protein area under the curve, NTproBNP N-terminal pro-brain natriuretic peptide.